title: Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen.
abstract: Transgenic (TG) mice were generated selectively expressing the gag protein of Friend murine leukemia virus (FMuLV) in the liver. FMuLV(gag) is also expressed by the FBL leukemia, and is the immunodominant tumor Ag of the CD8(+) T cell response in C57BL/6 mice. gag-TG mice expressing FMuLV(gag) in the liver were tolerant to the protein and failed to generate a CTL response to either FBL or FMuLV(gag). This tolerance reflected anergy rather than deletion, as CTL responsiveness could be recovered after four cycles of in vitro stimulation. Adoptively transferred gag-specific T cells were not anergized in gag-TG recipients, as revealed by antitumor activity in vivo. Also, such T cells did not induce detectable autoimmune injury in gag-TG liver cells. These results suggest that the requirements for a tissue Ag to provide a tolerizing stimulus are distinct from those for being the target of a T cell-mediated autoimmune response and that the requirements for induction and maintenance of peripheral tolerance are distinct for naive and primed T cells. That anergic T cells reactive with tumor-associated Ags can be recovered by repetitive in vitro stimulation and can mediate tumor therapy suggests strategies that use such Ags to generate CTL for adoptive immunotherapy should be further developed.
authors.affiliation: Department of Immunology and Division of Oncology, University of Washington, Seattle, WA 98195, USA.
authors.forename: C
authors.initials: C
authors.lastname: Ohlén
authors.forename: M
authors.initials: M
authors.lastname: Kalos
authors.forename: D J
authors.initials: DJ
authors.lastname: Hong
authors.forename: A C
authors.initials: AC
authors.lastname: Shur
authors.forename: P D
authors.initials: PD
authors.lastname: Greenberg
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000096:biosynthesis*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000637:transplantation / Q000821:virology; D002478:Cells, Cultured; D003433:Crosses, Genetic; D003602:Cytotoxicity, Immunologic / Q000235:genetics; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D005622:Friend murine leukemia virus / Q000235:genetics / Q000276:immunology; D015683:Gene Products, gag / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D007108:Immune Tolerance / Q000235:genetics; D016219:Immunotherapy, Adoptive / Q000379:methods; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology* / Q000628:therapy; D008099:Liver / Q000276:immunology / Q000378:metabolism / Q000821:virology; D008213:Lymphocyte Activation / Q000235:genetics; D017710:Lymphocyte Transfusion; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D012192:Retroviridae Infections / Q000276:immunology* / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000637:transplantation / Q000821:virology; D014407:Tumor Cells, Cultured / Q000637:transplantation; D014412:Tumor Virus Infections / Q000276:immunology* / Q000628:therapy
chemical_list: D000951:Antigens, Neoplasm; D018984:Epitopes, T-Lymphocyte; D015683:Gene Products, gag